Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 11/20 | 0.42 |
| ▸ | PPARA | Q07869 | 10/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922139 | 0.79 | ALDH1A1 (0.52) | ALDH1A1PKMCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13791613 | 0.77 | ALDH1A1 (0.54) | ALDH1A1PKMCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7433903 | 0.76 | ALDH1A1 (0.73) | ALDH1A1PKMCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4928860 | 0.76 | ALDH1A1 (0.47) | ALDH1A1PKMPPARGPPARACYP1A2 | |
| SCHEMBL4927984 | 0.75 | ALDH1A1 (0.50) | ALDH1A1PKMCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4927981 | 0.75 | ALDH1A1 (0.50) | ALDH1A1PKMCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4930275 | 0.75 | ALDH1A1 (0.50) | ALDH1A1PKMKDM4ELMNAMAPT | |
| SCHEMBL4923939 | 0.73 | ALDH1A1 (0.46) | ALDH1A1PKMCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4929847 | 0.70 | ALDH1A1 (0.48) | ALDH1A1PKMCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4925499 | 0.69 | ALDH1A1 (0.47) | ALDH1A1PKMCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | NOVO NORDISK A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | NOVO NORDISK A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | NOVO NORDISK A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| EP-1765814-A1 | CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006003096-A1 | CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | GLP1R, GIPR, GCGR | ALDH1A1 2002/4885PKM 2177/4885PPARG 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.